- I love science.
I love the world of discovery.
I love the possibility of imagining how things might be.
And I feel that the field of science is a ennobling.
(gentle music)
When I started in university,
I began to read about the immune system,
and one of the intriguing aspects of the immune system
was its ability to distinguish
between self and non-self,
to distinguish between you and me.
(gentle music)
What I loved about immunology,
and it may seem a little counterintuitive
and maybe not very scientific,
was you spend a lot of your time hypothesizing,
coming up with models.
This could be this because of this
and ABC goes to here, DO doesn't fit, okay.
So really, it was a bit like pieces of a puzzle,
and really lovely because it stimulated
so much the imagination.
And T cells seem to be the big players.
They seem to be the orchestrators of the immune response.
(gentle music)
So when we think, for example, in the case of COVID-19,
all these antibody responses,
well, the ability of the B cell
to produce antibody for sure depends
on its ability to recognize the foreign antigen,
in this case, it's SARS COV-2,
but they require help from T cells.
So already, you can see T cells
are helping B cells do what they do.
But T cells, also, are endowed
with their own ability to differentiate.
(gentle music)
Like B cells, T cells become activated
by recognizing foreign antigen.
Now, for a T cell to react against a foreign antigen,
it has to interact with an antigen presenting cells,
such as a dendritic cell.
Dendritic cells process and present antigen
on the cell surface.
The antigen is presented
by the major histocompatibility complex.
The T cell makes initial contact most probably
because the dendritic cell releases chemoattractants
that bring the T cell into close proximity with itself.
A receptor called the T cell receptor binds
to the MHC complex,
but this is then followed by various events
that cause the T cell contact
with the antigen presenting cell to become reinforced.
And that reinforcement of binding
is accompanied by a rearrangement of receptors
that are needed to generate signals in T cells.
(gentle music)
What was not known at the time
was how these receptors were transmitting signals
into T cells
to activate the T cells, one,
and secondly, to induce the differentiation of T cells.
And in 1984, it was clear that the T cell receptor,
recognizing for an antigen, could mediate signals,
leading to the activation of T cells,
and at the same time, were identified the CD4
and CD8 co-receptors that define subsets of cells.
So these co-receptors bind to
the major histocompatibility antigens
that present foreign antigen to T cells,
reinforcing the ability of the T cell
to bind to the MHC peptide complex.
There were still big questions.
And the most basic was how does
this T cell receptor complex actually activate cells?
And secondly, was there any role at all
for tyrosine phosphorylation in T cells
that might accompany the activation of these cells?
Many receptors, very clearly inside the cell,
there is a domain structure that is a kinase domain.
The activity of these kinase domains
were shown by many people to be needed for the activation
of cells induced by these receptors.
But nothing of the kind existed for the T cell receptor.
And because of my interest in the SRC family,
what about SRC family members, SRC kinases,
induced cancer via these SRC family members?
And at the time it was really unclear
how these SRC kinases operated in normal cells.
They had been implicated
and retrovirally induced transformation of cells.
At this point, a role for cellular forms
of SRC hadn't been identified.
Here's the T cell receptor.
The big question is why in heaven's name
is it so complicated?
You have the inner part,
which has the T cell receptor
that binds to the peptide as presented by the MHC complex.
It had been shown to associate with the CD3 sub units,
as well as a primarily intercellular chain
called the zeta chain.
But there was no evidence of the involvement
of kinase domains within this complex.
And we had various scenarios we imagined.
Well, if the T cell receptor isn't inducing
a phosphorylation cascade,
well maybe there's some mysterious cytokine receptor
hanging about somewhere that no one has discovered before
that has this kind of classic intercellular kinases domain
that may proceed TCR ligation.
And we even thought, well, perhaps,
given that the T cell receptor
and it's associated chains have unique structures,
maybe they don't even employ tyrosine phosphorylation
as a mechanism.
Maybe T cells just are fundamentally different
from other cells.
But always in the back of my mind
was maybe during evolution,
there was also co-evolution
of immune cell specific signaling proteins in immune cells
that adapted itself to the unique structures
on the cell surface,
that knowing that T-cells become activated
to elicit really different kinds of functions
that you don't find in other cell types,
that there must be some kind of immune specific component
to all of this.
And in the back of my mind, always,
I was thinking of CD8 and CD4,
which had been thought previously
just to reinforce the presentation of antigen,
that this would be an excellent way to activate cells,
if indeed the rest of the T cell receptor complex
had no clear link to tyrosine phosphorylation.
In the early days,
in comparing the cytoplasmic tails of CD4 and CD8,
I identified a motif that was shared between the two.
So that gave me a hint that something might be going on.
(gentle music)
The Eureka experiment was so exciting at the time.
We used anti CD4 and CD8,
we would precipitate out of lysates from T cells.
We would add B32, a substrate for kinases,
to the purified immuno precipitate.
Also, enolase was included in the immuno precipitates.
We let it incubate for a period of time
and then we could run it out on a gel.
We saw a very strong band at about 55-60.
In addition, as you can see in lane one,
the enolase band below.
When I first saw that result, I was stunned.
But of course, we repeated it many, many times.
It was clear there was lots of kinase activity associated
with CD4 and CD8.
We just didn't know what kind of kinase was there.
But what we did notice when we looked
at the phosphoryl signatures,
that all of the phosphorylation was in tyrosine,
on the tyrosine residue.
We could see nothing on threonine serine.
(gentle music)
So at the time, given my interest in SRC kinases,
I was aware that PB60 SRC
had a molecular weight around 60 kD.
And here we had these heavily labeled bands
at about 55 to 60 kD.
So that really suggested
that we might be dealing with a SRC kinase.
So the next step was for us to take an antibody
of a SRC-like kinase, called lystra,
roughly in that molecular range,
and again, we ran the assays.
And as you'll see in panel B, in lanes 3 and 4,
it was very clear.
A SRC family member, tyrosine kinase, called the Lck,
was precipitated associated with CD4 and CD8.
So this was really exciting,
because for the first time,
it implicated a tyrosine kinase linked
to a surface receptor on T cells,
which in turn, was active in reinforcing contact
during antigen presentation with the T cell receptor
while it was responding and generating signals.
So it made great sense.
We then ran a second experiment
where in this case, what we did is we added two antibodies,
one against the T cell receptor, one against CD4,
and we then carried out a precipitation
and then ran it on a 2D gel.
And what we were able to see was a CD3 gamma delta
and epsilon chains, as well as a zeta chain.
So each of these chains was being phosphorylated by Lck.
So that was the next step. It made sense.
Here you have CD4 coming in or CD8
phosphorylating the T cell receptor.
And subsequent analysis of the sequence
of these chains identified a conserved motif
which has two tyrosines separated by 10 to 12 amino acids,
which is now called an immuno receptor tyrosine based
activation motif, or an ITAM motif.
(gentle music)
And here you can see how the model unfolds.
We have CD4 or could be CD8 binding to Lck.
Lck then phosphorylates ITAMs within the CD3 chains
as well as within the zeta chain.
This then allows for the recruitment
of a second immune specific protein tyrosine kinase.
So here we now have two immune specific tyrosine kinase,
is one Lck, a second, ZAP-70.
(gentle music)
The work that we did,
identifying tyrosine phosphorylation cascade in T cells,
leading to the identification of specific motifs
that are needed to generate signals in cells,
led to their being used in something
called chimeric antigen receptors.
And these are receptors that have a outside domain
which is essentially an antibody
that will recognize a tumor associated antigen.
(gentle music)
You can take these designer molecules,
you can put them in T cells and put them back into patients.
(gentle music)
And they proved very effective in certain cancers,
saving thousands of lives.
And the race is on to make new kinds of CARs
that are more and more effective,
in particular, able to penetrate solid tumors,
because this is where the real challenge lies.
So in summary, the work we defined a role
for SRC family kinases in normal receptor signaling.
In the case of CD4 and CD8-p56lck,
these initiate T cell activation
and are responsible for initiating
a phosphorylation cascade.
And the discovery that SRC kinases
can interact with receptors led to a renewed interest
on behalf of pharmaceutical companies
to design new drugs,
in particular drugs that were inhibitory
with the idea in mind that these would be useful
in treating autoimmune diseases.
And as I just mentioned,
I believe our early work has led to new therapies
that have helped to cure patients of cancer.
So I'm very much motivated by the hope
that some of the things that we discover
will make the world a better place.
(gentle music)